Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Otopeni – page 43

679 clinical trials in Otopeni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Otopeni at a glance
679
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

679 trials in Otopeni

Open in trial search

Hepatitis D+1

Not recruiting

Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Study of Efgartigimod for Adults with Thyroid Eye Disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Effectiveness and Safety of Osimertinib for Patients with Early-Stage Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bayer AG

Study of SPI-62 for Treating ACTH-Dependent Cushing's Syndrome in Patients with Cushing's Disease or Ectopic ACTH/CRH Secretion

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Hyperadrenocorticism

Not recruiting

Study of SPI-62 for Treating Cushing's Syndrome in Patients with Benign Adrenal Tumors

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Clofutriben
  • Sponsor:Sparrow Pharmaceuticals Inc.

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Eteplirsen
  • Sponsor:Sarepta Therapeutics Inc.

Study Comparing Sacituzumab Govitecan to Physician's Choice Treatment for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic hepatitis B

Not recruiting

Study of tenofovir disoproxil versus placebo for children aged 2-12 years with chronic hepatitis B infection

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Tenofovir Disoproxil
  • Sponsor:Gilead Sciences Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Otopeni

What the registry says about research in the country

01 Lung Cancer Research

Investigating innovative treatments for non-squamous non-small cell lung cancer (NSCLC), with a focus on patients exhibiting specific genetic markers like c-Met overexpression. Studies are evaluating the effectiveness of targeted therapies compared to standard treatments.

  • EGFR wildtype NSCLC
  • Treatment resistance patterns
  • Targeted therapy approaches

Research aims to improve survival rates and treatment outcomes for lung cancer patients.

02 Urological Oncology

Comprehensive studies focusing on renal cell carcinoma and high-risk prostate cancer. Clinical trials are exploring combination therapies and novel treatment approaches including hormone therapy with radiation treatment.

  • Advanced kidney cancer treatments
  • Prostate cancer management
  • Combination therapy efficacy

Research centers on improving disease-free survival and treatment outcomes.

03 Skin Cancer Studies

Groundbreaking research in advanced melanoma treatment, investigating the potential of combination immunotherapy approaches. Studies are comparing various therapeutic combinations to establish optimal treatment protocols.

  • Immunotherapy combinations
  • Advanced melanoma management
  • Treatment effectiveness markers

Focus on developing more effective first-line treatments for unresectable melanoma.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.